KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Abbott Laboratories (ABT) Other Operating Expenses (2016 - 2026)

Abbott Laboratories' Other Operating Expenses history spans 18 years, with the latest figure at $5.3 billion for Q1 2026.

  • On a quarterly basis, Other Operating Expenses rose 8.67% to $5.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $21.4 billion, a 4.32% increase, with the full-year FY2025 number at $21.0 billion, up 2.03% from a year prior.
  • Other Operating Expenses hit $5.3 billion in Q1 2026 for Abbott Laboratories, down from $5.3 billion in the prior quarter.
  • Over the last five years, Other Operating Expenses for ABT hit a ceiling of $5.5 billion in Q1 2022 and a floor of $4.8 billion in Q1 2023.
  • Historically, Other Operating Expenses has averaged $5.2 billion across 5 years, with a median of $5.1 billion in 2022.
  • Biggest five-year swings in Other Operating Expenses: grew 12.0% in 2022 and later fell 12.31% in 2023.
  • Tracing ABT's Other Operating Expenses over 5 years: stood at $5.1 billion in 2022, then decreased by 1.02% to $5.0 billion in 2023, then increased by 7.35% to $5.4 billion in 2024, then decreased by 1.17% to $5.3 billion in 2025, then fell by 0.6% to $5.3 billion in 2026.
  • Business Quant data shows Other Operating Expenses for ABT at $5.3 billion in Q1 2026, $5.3 billion in Q4 2025, and $5.5 billion in Q3 2025.